Renal Cell Carcinoma:
————————————————————————————————————————————————————————————-
Current and Emerging Standards in Systemic Therapy
January 31st, 2021
7:30 am -10:15 am PST
Held Virtually on Zoom
Overview
This continuing medical education (CME) activity (live webinar and enduring materials) Renal Cell Carcinoma: Current and Emerging Standards in Systemic Therapy, is intended to improve the care of kidney cancer patients by educating oncologists, nurses, pharmacists, and other healthcare providers about the latest developments in the field. The Renal Cell Carcinoma: Current and Emerging Standards in Systemic Therapy brings together renowned experts in the field. They will share patient case scenarios commonly encountered in clinical practice and will provide learners practical methods to optimize therapy.
Emerging data across the spectrum of kidney cancer management will be reviewed and discussed, from early stage to metastatic disease. The panel of experts will also discuss how they are applying this information to their practices right now, as well as potential future implications.
Target Audience
- Oncologists
- Residents/Fellows
- NPs/PAs
- Pharmacists
- Nurses
Educational Objectives
At the conclusion of the activity, participants will be able to:
- Describe the pathogenesis, and common molecular abnormalities noted in Renal Cell
Carcinoma (RCC). - Discuss the management of localized RCC with emphasis on the role of adjuvant systemic
therapy. - Identify optimal first-line management of metastatic or advanced RCC
- Review the second or later lines of treatment of advanced/metastatic RCC with emphasis on molecular markers.
Course Highlights
- An innovative and integrated learning environment.
- Core competencies covered include patient care/patient-centered care, medical knowledge, system-based practice, and practice-based learning and improvement.
- Livestream delivery method allows ample opportunities to network with colleagues and interacts with faculties; enduring materials allow learners opportunities to learn at their convenience.
- Program topics can immediately be applied to clinical practice.
Faculty
Dr. Toni K. Choueiri
Lank Center for Genitourinary Oncology
Dr. Arpita Desai
UC San Francisco
Dr. Shuchi Gulati
University of Cincinnati
Dr. Alice Fan
Stanford
Moderator
Dr. Siddhartha Yadav
Mayo Cancer Clinic
CME Credit Statement
The Binaytara Foundation is accredited by the Washington State Medical Association to provide continuing medical education for physicians.
The Binaytara Foundation designates this live activity for a maximum of 2.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
This activity meets the criteria for up to 2.0 hours of Category I CME credit to satisfy the relicensure requirements of the Washington State Medical Quality Assurance Commission.
Nursing Contact Hours: Provider approved by the California Board of Registered Nursing, Provider # CEP17035, for 2.0 Contact Hours.
ABSM Maintenance of Certificate Recognition Statement: Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 2.0 Medical Knowledge MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.
Independence & Integrity of this educational Activity
Disclosure of Off-Label Product:
This activity will include the following discussion of off-label product (s):
HIF2 inh, TKI or IO outside current indication, and not FDA approved – discussed by Dr. Toni K Choueiri
Disclosure of Relevant Financial Relationships
All relevant financial relationships have been identified and mitigated for everyone in control of the contents of this activity before their participation in this educational activity. No member of the activity planning committee or faculty has any relevant financial relationship with an ACCME defined ineligible entity with the exception of:
- Arpita Desai, MD – Ineligible entity: Dendreon Pharmaceuticals; Nature of relationship: Advisory Board;
- Toni K Choueiri, MD – Ineligible entities: Pfizer, Exelixis, Roche, Merck, BMS, Roche, Novartis, GSK, Peloton; Nature of relationship: Research support and Consultant
Disclosure of Commercial Support
This activity has been supported by independent medical education grant from Exelixis, Inc.